Cytochrome P450 in Cancer Susceptibility and Treatment

被引：88

作者：

Mittal, Balraj ^{[1
]}

Tulsyan, Sonam ^{[1
]}

Kumar, Surendra ^{[1
]}

Mittal, Rama Devi ^{[2
]}

Agarwal, Gaurav ^{[3
]}

机构：

[1] Sanjay Gandhi Post Grad Inst Med Sci, Dept Genet, Lucknow, Uttar Pradesh, India

[2] Sanjay Gandhi Post Grad Inst Med Sci, Dept Urol & Renal Transplant, Lucknow, Uttar Pradesh, India

[3] Sanjay Gandhi Post Grad Inst Med Sci, Dept Endocrine Surg, Lucknow, Uttar Pradesh, India

来源：

ADVANCES IN CLINICAL CHEMISTRY, VOL 71 | 2015年 / 71卷

关键词：

SQUAMOUS-CELL CARCINOMA; GLUTATHIONE-S-TRANSFERASE; HUMAN LIVER-MICROSOMES; GASTROINTESTINAL STROMAL TUMORS; ACUTE LYMPHOBLASTIC-LEUKEMIA; NORTH INDIAN POPULATION; POSITIVE BREAST-CANCER; RIO-DE-JANEIRO; PHASE-II TRIAL; METABOLIZING ENZYME POLYMORPHISMS;

D O I：

10.1016/bs.acc.2015.06.003

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Cytochrome 450 (CYP450) designates a group of enzymes abundant in smooth endoplasmic reticulum of hepatocytes and epithelial cells of small intestines. The main function of CYP450 is oxidative catalysis of various endogenous and exogenous substances. CYP450 are implicated in phase I metabolism of 80% of drugs currently in use, including anticancer drugs. They are also involved in synthesis of various hormones and influence hormone-related cancers. CYP450 genes are highly polymorphic and their variants play an important role in cancer risk and treatment. Association studies and meta-analyses have been performed to decipher the role of CYP450 polymorphisms in cancer susceptibility. Cancer treatment involves multimodal therapies and evaluation of CYP450 polymorphisms is necessary for pharmacogenetic assessment of anticancer therapy outcomes. In addition, CYP450 inhibitors are being evaluated for improved pharmacokinetics and oral formulation of several anticancer drugs.

引用

页码：77 / 139

页数：63

共 50 条

[1] Cancer treatment and pharmacogenetics of cytochrome P450 enzymes
van Schaik, RHN
INVESTIGATIONAL NEW DRUGS, 2005, 23 (06) : 513 - 522
[2] Cancer treatment and pharmacogenetics of cytochrome P450 enzymes
Ron H. N. van Schaik
Investigational New Drugs, 2005, 23 : 513 - 522
[3] Role of cytochrome P450 phenotyping in cancer treatment
Dees, EC
Watkins, PB
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (06) : 1053 - 1055
[4] Cytochrome P450 pharmacogenetics and cancer
Rodriguez-Antona, C
Ingelman-Sundberg, M
ONCOGENE, 2006, 25 (11) : 1679 - 1691
[5] Cytochrome P450 pharmacogenetics and cancer
C Rodriguez-Antona
M Ingelman-Sundberg
Oncogene, 2006, 25 : 1679 - 1691
[6] Genotyping and phenotyping cytochrome P450: Perspectives for cancer treatment
Mathijssen, RHJ
van Schaik, RHN
EUROPEAN JOURNAL OF CANCER, 2006, 42 (02) : 141 - 148
[7] Gene polymorphism of cytochrome P450 significantly affects lung cancer susceptibility
Li, Meng
Li, Anqi
He, Ruiqing
Dang, Wenhui
Liu, Xinyu
Yang, Tian
Shi, Puyu
Bu, Xiang
Gao, Dan
Zhang, Ning
Du, Shuli
Jin, Tianbo
Chen, Mingwei
CANCER MEDICINE, 2019, 8 (10): : 4892 - 4905
[8] Measurement of cytochrome P450 and NADPH–cytochrome P450 reductase
F Peter Guengerich
Martha V Martin
Christal D Sohl
Qian Cheng
Nature Protocols, 2009, 4 : 1245 - 1251
[9] Genetically modified macrophages expressing hypoxia regulated cytochrome P450 and P450 reductase for the treatment of cancer
Kan, On
Day, Debbie
Iqball, Sharifah
Burke, Frances
Grimshaw, Matthew J.
Naylor, Stuart
Binley, Katie
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2011, 27 (02) : 173 - 180
[10] Cytochrome P450
P. H. Roos
N. Jakubowski
Analytical and Bioanalytical Chemistry, 2008, 392 : 1015 - 1017

← 1 2 3 4 5 →